📅 22–25 September | 📍 Boston, MA
We are pleased to announce that Bill Keating, Chief Commercial Officer, Diagnostics and Healthcare at PrecisionLife, will be presenting at the World Clinical Biomarkers and Companion Diagnostics Summit 2025.
Bill will discuss how PrecisionLife is pioneering the next generation of mechanism-based diagnostics to extend the impact of precision medicine beyond oncology and into the world’s most common and costly chronic diseases.
Our novel approach reveals the biological mechanisms that drive disease, enabling the development of rapid, non-invasive genotyping tests that:
Predict lifetime risk of disease
Accelerate diagnosis and triage
Enrich recruitment for clinical trials
Deliver clinically actionable results to improve health outcomes and reduce the costs of care
With chronic diseases accounting for more than 80% of global healthcare spending, this represents a significant opportunity to reshape care pathways and improve the lives of billions of patients worldwide.
Bill brings over 30 years of experience in product development, market introductions, and strategic partnerships across novel diagnostic technologies. His work has contributed to multiple FDA-cleared platforms and assays, and he has held leadership roles at Becton Dickinson, Philips Healthcare, Foundation Medicine, and a number of innovative early-stage companies.
Title: Enabling Precision Medicine Beyond Oncology for Complex, Chronic Diseases
Track: Leveraging AI-enabled Platforms for Patient-Centric Precision Medicine
Date: 25 September
Time: 2.30PM
To learn more about the event, visit: World Clinical Biomarkers and Companion Diagnostics Summit